Aliada Therapeutics

Founded in 2021 and based in Massachusetts, US, Aliada Therapeutics, Inc. is engaged in developing drug delivery systems. The company was formed through a merger and has completed 3 deals.4 billion. Sanjaya Singh co-founded the firm. The company offers therapeutic solutions designed to facilitate the transport of large-molecule cargoes across the blood-brain barrier (BBB). Central to their offerings is the Modular Delivery (MODEL) platform, which leverages small modular protein domains engineered for optimal stability and developability. This platform has been specifically tailored to utilize native transcytosis pathways, enabling the effective movement of therapeutic agents into the brain. The company focuses on creating fit-for-purpose therapeutics applicable to multiple targets and modalities, including a flagship bispecific antibody targeting pyroglutamate amyloid beta (3pE-Aß) and the transferrin receptor (TfR). Aliada’s products are aimed at addressing significant neurological conditions, with applications anticipated primarily in North America and Europe, where the need for effective brain-targeted therapies is increasingly recognized.  Aliada Therapeutics' revenue generation is primarily driven through partnerships and collaborations within the biotechnology and pharmaceutical sectors. The company engages in strategic alliances that facilitate the development and commercialization of its therapeutic candidates, particularly those utilizing the MODEL platform. Revenue is generated through milestone payments, licensing agreements, and potential royalties stemming from successful product development and market introduction. Their flagship products, such as the bispecific antibody targeting 3pE-Aß, are positioned for commercial opportunities, particularly as they progress through clinical trials and into potential market release. The firm operates within a B2B framework, collaborating with established pharmaceutical companies and research institutions to maximize the therapeutic potential of its innovations.  In October 2024, AbbVie agreed to fully acquire Aliada Therapeutics, Inc.4 billion, enhancing its neuroscience portfolio by advancing Aliada's ALIA-1758 for Alzheimer's disease and leveraging its novel blood-brain barrier-crossing technology. The acquisition will support the acceleration of development for next-generation CNS therapies as Aliada aims to launch new products targeting neurological conditions. The company is focused on expanding its market presence in North America and Europe, where its solutions are positioned to meet growing needs.

1. Seed

   Jun 1, 2021

   Amount

   Undisclosed

   Investors

   Locked